story of the week
Sorafenib Compared With Capecitabine vs Placebo With Capecitabine in Advanced HER2− Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Breast Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer
Clin. Breast Cancer 2017 Dec 01;17(8)585-594.e4, J Baselga, C Zamagni, P Gómez, B Bermejo, SE Nagai, B Melichar, A Chan, L Mángel, J Bergh, F Costa, HL Gómez, WJ Gradishar, CA Hudis, BL Rapoport, H Roché, P Maeda, L Huang, G Meinhardt, J Zhang, LS SchwartzbergFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.